Pfizer has signed two diverse deals in quick succession following the announcement of the mega-merger with Wyeth just over a month ago. First to reach the news was the agreement with Aurobindo followed up with a deal with Bausch & Lomb. Both deals were done by different divisions and it demonstrates that small and targeted deal activity is ongoing even with the Wyeth merger continuing in the background.